LENZ Therapeutics (NASDAQ:LENZ) Coverage Initiated by Analysts at SVB Leerink

SVB Leerink started coverage on shares of LENZ Therapeutics (NASDAQ:LENZ) in a research note published on Monday, MarketBeat Ratings reports. The brokerage issued an outperform rating and a $32.00 price objective on the stock.

Other analysts have also issued reports about the company. William Blair assumed coverage on LENZ Therapeutics in a research note on Monday. They issued an outperform rating on the stock. Piper Sandler started coverage on LENZ Therapeutics in a research note on Wednesday, March 27th. They set an overweight rating and a $28.00 target price for the company. Finally, Citigroup started coverage on LENZ Therapeutics in a research note on Wednesday, April 10th. They set a buy rating and a $34.00 target price for the company.

LENZ Therapeutics Price Performance

NASDAQ LENZ opened at $20.44 on Monday. The firm has a market cap of $170.06 million, a price-to-earnings ratio of -1.31 and a beta of 0.20. LENZ Therapeutics has a fifty-two week low of $14.07 and a fifty-two week high of $29.82.

Insiders Place Their Bets

In other LENZ Therapeutics news, Director Ra Capital Management, L.P. bought 998,009 shares of the stock in a transaction on Thursday, March 21st. The stock was purchased at an average price of $15.03 per share, with a total value of $15,000,075.27. Following the completion of the purchase, the director now owns 3,319,339 shares in the company, valued at $49,889,665.17. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Insiders own 38.40% of the company’s stock.

About LENZ Therapeutics

LENZ Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing aceclidine-based eye drop to enhance vision in patients diagnosed with presbyopia. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.